Cas:27301-46-8 5-(4-methoxyphenyl)-1,3-diphenylpyrazole manufacturer & supplier

We serve Chemical Name:5-(4-methoxyphenyl)-1,3-diphenylpyrazole CAS:27301-46-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-(4-methoxyphenyl)-1,3-diphenylpyrazole

Chemical Name:5-(4-methoxyphenyl)-1,3-diphenylpyrazole
CAS.NO:27301-46-8
Synonyms:5-(4-methoxyphenyl)-1,3-diphenylpyrazole
Molecular Formula:C22H18N2O
Molecular Weight:326.39100
HS Code:2933199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:507.5ºC at 760mmHg
Density:1.11g/cm3
Index of Refraction:1.611
PSA:27.05000
Exact Mass:326.14200
LogP:5.21490

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-(4-methoxyphenyl)-1,3-diphenylpyrazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-methoxyphenyl)-1,3-diphenylpyrazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-methoxyphenyl)-1,3-diphenylpyrazole Use and application,5-(4-methoxyphenyl)-1,3-diphenylpyrazole technical grade,usp/ep/jp grade.


Related News: But several border points remain open, and many medical workers fear that Hong Kong��s well-regarded health care system will be overwhelmed. 5-(4-methoxyphenyl)-1,3-diphenylpyrazole manufacturer The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 5-(4-methoxyphenyl)-1,3-diphenylpyrazole supplier But several border points remain open, and many medical workers fear that Hong Kong��s well-regarded health care system will be overwhelmed. 5-(4-methoxyphenyl)-1,3-diphenylpyrazole vendor The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 5-(4-methoxyphenyl)-1,3-diphenylpyrazole factory This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.